Aphria Achieves a Critical Milestone in Germany — Will Its Stock Surge?

Investors in Aphria stock will welcome this new growth catalyst.

stocks rising

Image source: Getty Images

Canadian pot producer Aphria (TSX:APHA)(NASDAQ:APHA) has propped up its already outperforming stock after announcing a critical milestone in October. Investors in Aphria stock may look forward to better days after the company successfully made its first-ever shipment of medical cannabis to a new market: Germany.

Aphria’s new strategic milestone

The company finally shipped its first-ever medical marijuana product to Germany this month. In a press release published on Wednesday, company CEO, Irwin D. Simon was upbeat, stating that the shipment of dried flower products represented “another significant milestone for Aphria” that strengthened its position as a leading cannabis firm in the European Union.

The critical question from APHA stock investors today could be, “How is this a key achievement?”

One piece of APHA’s expansion strategy falls into place

More than half of Aphria’s revenue currently comes from Germany. But it’s in the form of low margin pharmaceuticals distribution revenue, with zero cannabis sales.

The Germany medical marijuana market is expected to be significantly larger than the Canadian medical and recreational markets combined. Pot companies from all over the world are scrambling for a piece of this most developed medical cannabis market in Europe. While Dutch and Canadian marijuana firms lead the pack, Aphria has not been a participant in the game.

Unfortunately, the Germany cannabis market hasn’t been accessible to APHA for years.

Tight production and import regulations shroud in EU Good Manufacturing Practices (EU GMP) certifications have been a hindrance to many interested suppliers. Aphria made a false start by getting cGMP certification from the U.S.A. around the time it acquired Nuuvera Inc. This was not the required certification for medical marijuana exports to European markets.

Finally, after receiving the correct certifications last year, the company has entered the high margin Germany medical cannabis market. Encouragingly, its subsidiary CC Pharma has distribution access to over 13,000 pharmacies in the European country.

Will Aphria’s stock price surge?

The news is good, but APHA stock price only increased by about 3% post the release. Something is missing in the company’s press release. The numbers are missing!

We know that finding a new growth market is necessary. Aphria ramped up its pot production this year after receiving new licenses. But the Canadian market has been too slow to grow. There’s a need to find new buyers for excess production. The company needs new markets.

Most noteworthy, cannabis exports to Germany will boost gross margins, sustain revenue growth, and allow the company to offload inventor, which is critical. A high production run rate is necessary for the company to keep its per-unit cash costs low. A recent 3,000-kilograms-per-year supply deal to Israel wasn’t enough to absorb excess inventory.

As highlighted above, details on how many grams of pot were actually shipped to Germany aren’t disclosed yet. Therefore, we can’t really tell if the latest milestone achievement has moved any needles yet.

That said, I would expect the latest export to be the first of many, even after the company completes its first facility in Germany for local production. This news piece was one of my expected growth drivers for Aphria stock. Shares should continue to rise as the company executes for growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Investing

Target. Stand out from the crowd

2 Canadian Stocks I’m Buying Lots of This Year

I’m looking to snatch up exciting Canadian stocks like VieMed Healthcare Inc. (TSX:VMD) throughout 2023.

Read more »

grow money, wealth build
Dividend Stocks

Got $3,000? 3 TSX Growth Stocks to Buy in January 2023

Top TSX growth stocks that look appealing for 2023.

Read more »

woman data analyze
Dividend Stocks

Need Passive Income? Turn $15,000 Into $851 Annually

This passive-income stock is already climbing higher, up 16% in the last three months! Yet it's still valuable, so you…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

Retirees: 3 Reliable Canadian Dividend Stocks to Buy Now for Passive Income

Top TSX dividend stocks now appear oversold.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.

2 TSX Stocks Safer for Investing in a Recession

These consumer companies will likely beat the broader market averages amid a recession. These stocks offer stability, income, and consistent…

Read more »

Dividend Stocks

For $100 in Passive Income Each Month, Buy 1,500 Shares of This REIT

REITs such as Northwest Healthcare can enable investors create a passive-income stream as well as benefit from capital gains.

Read more »

A colourful firework display
Dividend Stocks

2 Canadian Growth Stocks (With Dividends) to Start 2023 With a Bang

Here are two of the best dividend-paying Canadian growth stocks you can invest in at the start of 2023 and…

Read more »

sale discount best price
Dividend Stocks

4 Insanely Cheap Canadian Stocks to Buy for Passive Income

The recent bear market has created some incredible bargains, especially for those looking for passive income. Here are four cheap…

Read more »